STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder

Trial Profile

STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Bupropion/dextromethorphan (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Acronyms STRIDE-1
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 07 Mar 2017 According to an Axsome Therapeutics media release, top-line results from this study are expected in 1Q 2018.
    • 14 Feb 2017 According to an Axsome Therapeutics media release, the US FDA has granted Fast Track Designation for AXS-05 for the treatment of resistant depression.
    • 17 Mar 2016 Status changed from planning to recruiting, according to an Axsome Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top